Prostate cancer

Radiotherapy with androgen deprivation therapy (ADT) improves survival compared with ADT alone

Men with locally advanced prostate cancer (without spread) who receive radiotherapy (RT) on top of their androgen deprivation therapy (ADT) have greater overall survival compared with men on ADT alone, according to Dr Padraig Warde, Radiation Medicine Programme, Princess Margaret Hospital, Toronto, Canada, Matthew R Sydes, MRC Clinical Trials Unit, London, UK, and Dr Malcolm Mason, Cardiff University School of Medicine, Wales, and colleagues. 

The advantages of combined treatment, they conclude in their article published Online First by The Lancet, should be discussed with all men with this condition. This trial, the first that has been adequately powered to compare these two treatment strategies, assessed patients with locally advanced (T3 or T4) prostate cancer (n=1057); or organ-confined disease (T2) with either a prostate-specific antigen (PSA) concentration more than 40 ng/mL (n=119) or PSA concentration more than 20 ng/mL and a Gleason score of 8 or higher (n=25) Patients were randomly assigned to receive lifelong ADT and RT, or ADT only.1,205 patients were randomly assigned (602 in the ADT onlygroup and 603 in the ADT andRT group); median follow-upwas six years. At the time of analysis, a total of 320 patients had died, 175 in the ADT only group and 145 in the ADT and RT group. The addition of RT to ADT improved overall survival at seven years (74% ADT/RT vs. 66% ADT). Serious long-term genitourinary or gastrointestinal toxicity from RT was uncommon and low numbers of serious adverse events were recorded in each group. 

‘This trial provides convincing evidence that local control of disease in the prostate improves survival in patients with locally advanced prostate cancer,’ the authors say, concluding: ‘Our findings suggest that the benefits of the combination of ADT and RT should be discussed with all patients considering a curative treatment approach.’
 

19.12.2011

Read all latest stories

Related articles

Photo

An unexpected and novel target

How our biological clock could save us from prostate cancer

Our biological or circadian clock synchronizes all our bodily processes to the natural rhythms of light and dark. It’s no wonder then that disrupting the clock can wreak havoc on our body. In fact,…

Photo

Hormone-Upregulated lncRNA

Early detection of prostate cancer and alternative to invasive biopsies

Pioneering research conducted by University of Virginia in collaboration with Manchester UK based APIS Assay Technologies Ltd has discovered Hormone-Upregulated lncRNA within the lymphocyte-specific…

Photo

Early detection

Prostate cancer risk: The role of relatives

If a father or brother has prostate cancer, his son or brother has an increased risk of this type of cancer. Whether this also applies when precancerous stages of this cancer are discovered in…

Related products

Beckman Coulter – Prostate Health Index (phi)

Immunochemistry

Beckman Coulter – Prostate Health Index (phi)

Beckman Coulter, Inc.
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Subscribe to Newsletter